Esther Rajavelu

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Maegan Deare, Attorney-in-Fact for Esther Rajavelu
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Esther Rajavelu

Form 4 holding Chief Executive Officer, Chief Financial Officer and Chief Business Officer

Spero Therapeutics, Inc.

Security class
Common Stock
Shares / value
986,851
Estimated value
$2,476,996
Report date
04 May 2026
Price
$2.51
Ownership
Direct
Form 4 holding Chief Executive Officer, Chief Financial Officer and Chief Business Officer

Spero Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
498,000
Estimated value
Report date
02 Feb 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Financial Officer

Fulcrum Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
160,000
Estimated value
Report date
09 Feb 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Esther Rajavelu

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .